Hara N, Yoshida T, Furukawa T, Inokuchi K
Jpn J Surg. 1980 Sep;10(3):232-7. doi: 10.1007/BF02468753.
We have treated 40 patients with thymoma. All the 18 with benign thymoma were treated with resection alone and none had a tumor recurrence or died from disease-related causes. Postoperative survival in this group ranged from 2 months to 14 years. Of the 22 patients with malignant thymoma, 2 underwent total resection, 10 partial resection and 10 were non-resectable. Fifteen of the 20 patients with non-resectable and partially excised thymomas were given radiotherapy. The cumulative 5- and 10-year survival rate of irradiation treated patients was 45.6%, and 34.4%, respectively. Of 6 non-irradiated patients, only one who underwent complete excision of tumors survived for more than 10 years, and 5 died within 3 years after treatment. Based on our findings we suggest that all patients with malignant thymoma, irrespective of the extent of surgical treatment, should be given postoperative irradiation.
我们已治疗40例胸腺瘤患者。18例良性胸腺瘤患者均仅接受手术切除，无一例出现肿瘤复发或死于疾病相关原因。该组患者术后生存时间为2个月至14年。22例恶性胸腺瘤患者中，2例行全切除，10例行部分切除，10例无法切除。20例无法切除及部分切除胸腺瘤患者中，15例接受了放疗。接受放疗患者的5年和10年累积生存率分别为45.6%和34.4%。6例未接受放疗的患者中，仅1例肿瘤完全切除者存活超过10年，5例在治疗后3年内死亡。基于我们的研究结果，我们建议所有恶性胸腺瘤患者，无论手术治疗范围如何，均应接受术后放疗。
